# Clinical trials recruiting in Puerto Rico: 344 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 344 trials recruiting or not yet recruiting with a site in Puerto Rico, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Puerto Rico: 344 rows for $17.20, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 8 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/puerto-rico

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 344
- Recruiting or not yet: 344
- Read on: November 19, 2026

## Trials

The 25 newest of 344, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931573 | AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931573) |
| November 12, 2026 | NCT07931495 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931495) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 27, 2026 | NCT07897721 | A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Not yet recruiting | Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic... | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897721) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 9, 2026 | NCT07869043 | A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma | Pfizer | Phase 3 | Recruiting | Asthma | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869043) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| September 25, 2026 | NCT07840560 | Sleep Harmonization Via Bundled Team-Based Interventions in the ICU | University of California, San Diego | Not applicable | Not yet recruiting | Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium | 62,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840560) |
| September 16, 2026 | NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After... | Incyte Corporation | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823322) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| August 31, 2026 | NCT07795164 | Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH | Altimmune, Inc. | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795164) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 24, 2026 | NCT07782970 | A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps... | GlaxoSmithKline | Phase 3 | Recruiting | Nasal Polyps | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782970) |
| August 21, 2026 | NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early phase 1 | Not yet recruiting | MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778602) |
| August 20, 2026 | NCT07775300 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775300) |
| August 20, 2026 | NCT07775287 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent... | Genmab | Phase 3 | Recruiting | Colorectal Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775287) |
| August 14, 2026 | NCT07765095 | Pericapsular Nerve Group (PENG) Block on Postoperative Pain Management After Acetabular Fracture Fixation | University of Puerto Rico | Not applicable | Recruiting | Acetabular Fractures | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765095) |
| August 12, 2026 | NCT07759245 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Eli Lilly and Company | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759245) |
| August 10, 2026 | NCT07756645 | A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line... | AbbVie | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 940 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756645) |
| August 10, 2026 | NCT07754461 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Phase 3 | Recruiting | Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754461) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| Centro Comprensivo de Cancer de UPR | San Juan | 34 |
| San Juan City Hospital | San Juan | 28 |
| Doctors Cancer Center | Manati | 23 |
| Cancer Center-Metro Medical Center Bayamon | Bayamón | 14 |
| San Juan Community Oncology Group | San Juan | 14 |
| HIMA San Pablo Oncologic Hospital | Caguas | 13 |
| Puerto Rico Hematology Oncology Group | Bayamón | 13 |
| University Pediatric Hospital | San Juan | 13 |
| Pan American Center for Oncology Trials LLC | San Juan | 12 |
| Pan American Center for Oncology Trials, LLC | San Juan | 12 |
| FDI Clinical Research | San Juan | 10 |
| Latin Clinical Trial Center | San Juan | 9 |
| Auxilio Mutuo Cancer Center | San Juan | 8 |
| Pan American Center for Oncology Trials | Rio Piedras | 7 |
| PanOncology Trials | San Juan | 6 |
| San Jorge Children's Hospital | San Juan | 6 |
| Puerto Rico Health and Wellness Institute | Dorado | 5 |
| Ponce Medical School Foundation Inc. | Ponce | 5 |
| Dorado Medical Complex | Dorado | 4 |
| Pan American Center for Oncology Trials, LLC - Mayaguez Office | Mayagüez | 4 |
| Isis Clinical Research Center | Guaynabo | 4 |
| Instituto Oncologia Moderna Ponce | Ponce | 4 |
| Primary Care Physician Group | San Juan | 4 |
| GCM Medical Group, PSC - Hato Rey Site | San Juan | 4 |
| Solace Clinical Research | Bayamón | 4 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 13 |
| Phase 1/2 | 20 |
| Phase 2 | 63 |
| Phase 2/3 | 12 |
| Phase 3 | 175 |
| Phase 4 | 6 |
| Not applicable | 23 |
| Observational | 31 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 25 |
| Carcinoma, Non-Small-Cell Lung | 19 |
| Overweight | 17 |
| Colorectal Neoplasms | 16 |
| Diabetes Mellitus, Type 2 | 15 |
| Neoplasms | 14 |
| Breast Neoplasms | 14 |
| Neoplasm Metastasis | 14 |
| Colonic Neoplasms | 10 |
| Pancreatic Neoplasms | 9 |
| Leukemia, Myeloid, Acute | 9 |
| Lung Neoplasms | 9 |
| Ovarian Neoplasms | 9 |
| Prostatic Neoplasms | 8 |
| Alzheimer Disease | 8 |
| Cardiovascular Diseases | 7 |
| Depression | 7 |
| Esophageal Neoplasms | 7 |
| Endometrial Neoplasms | 7 |
| Recurrence | 6 |
| Multiple Myeloma | 6 |
| Dementia | 6 |
| Non-alcoholic Fatty Liver Disease | 6 |
| Stomach Neoplasms | 6 |
| Hypertension | 5 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 27 |
| National Cancer Institute (NCI) | 25 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 23 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 19 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 19 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 13 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 10 |
| Children's Oncology Group | 10 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 9 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 8 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 8 |
| University of Puerto Rico | 8 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 7 |
| NRG Oncology | 6 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 6 |
| Alliance for Clinical Trials in Oncology | 5 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 5 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 5 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 4 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 4 |
| SWOG Cancer Research Network | 4 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 4 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 4 |
| ECOG-ACRIN Cancer Research Group | 4 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
- [Uniform stores in the United States](https://specstream.ai/data/businesses/uniform-stores/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Home security companies in the United States](https://specstream.ai/data/businesses/home-security-companies/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
- [Window installers in the United States](https://specstream.ai/data/businesses/window-installers/united-states)
